Author’s reply to “Multicenter phase II trial of trastuzumab and docetaxel for HER2-positive salivary gland cancer”

Journal Article Author's reply to "Multicenter phase II trial of trastuzumab and docetaxel for HER2-positive salivary gland cancer" Get access Satoshi Kano , Satoshi Kano Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, N15, W7, Kita-ku, Sapporo, 060-8638, Japan https://orcid.org/0000-0003-4750-5332 Search for other works by this author on: Oxford Academic PubMed Google Scholar Ichiro Kinoshita , Ichiro Kinoshita Department of Medical Oncology, Hokkaido University Hospital, N14, W5, Kita-ku, Sapporo, 060-8648, Japan Search for other works by this author on: Oxford Academic PubMed Google Scholar Hirotoshi Dosaka-Akita Hirotoshi Dosaka-Akita Department of Medical Oncology, Hokkaido University Hospital, N14, W5, Kita-ku, Sapporo, 060-8648, Japan Corresponding author. Department of Medical Oncology, Hokkaido University Hospital, N14, W5, Kita-ku Sapporo 060-8648, Japan. E-mail: [email protected] Search for other works by this author on: Oxford Academic PubMed Google Scholar Japanese Journal of Clinical Oncology, hyaf138, https://doi.org/10.1093/jjco/hyaf138 Published: 01 September 2025 Article history Received: 07 August 2025 Revision requested: 08 August 2025 Accepted: 22 August 2025 Published: 01 September 2025